Display options
Cite
Kawai H, Tian F, Kurata T, et al. Prevention of hyperglycemic signal pathways in metabolic syndrome carotid artery of rats. Transl Stroke Res. 2012;3(4):466-72doi: 10.1007/s12975-012-0205-6.
Kawai, H., Tian, F., Kurata, T., Deguchi, K., Yamashita, T., Omote, Y., Kono, S., & Abe, K. (2012). Prevention of hyperglycemic signal pathways in metabolic syndrome carotid artery of rats. Translational stroke research, 3(4), 466-72. https://doi.org/10.1007/s12975-012-0205-6
Kawai, Hiromi, et al. "Prevention of hyperglycemic signal pathways in metabolic syndrome carotid artery of rats." Translational stroke research vol. 3,4 (2012): 466-72. doi: https://doi.org/10.1007/s12975-012-0205-6
Kawai H, Tian F, Kurata T, Deguchi K, Yamashita T, Omote Y, Kono S, Abe K. Prevention of hyperglycemic signal pathways in metabolic syndrome carotid artery of rats. Transl Stroke Res. 2012 Dec;3(4):466-72. doi: 10.1007/s12975-012-0205-6. Epub 2012 Aug 14. PMID: 24323833.
Copy Download .nbib Format: NLM
Share it on

Transl Stroke Res. 2012 Dec;3(4):466-72. doi: 10.1007/s12975-012-0205-6. Epub 2012 Aug 14.

Prevention of hyperglycemic signal pathways in metabolic syndrome carotid artery of rats.

Translational stroke research

Hiromi Kawai, Fengfeng Tian, Tomoko Kurata, Kentaro Deguchi, Toru Yamashita, Yoshio Omote, Syoichiro Kono, Koji Abe

Affiliations

  1. Department of Neurology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, 2-5-1 Shikatacho, Okayama, 700-8558, Japan.

PMID: 24323833 DOI: 10.1007/s12975-012-0205-6

Abstract

Obesity is the major risk factor for metabolic syndrome and atherosclerotic cardiocerebrovascular diseases and induces insulin resistance characterized by a dysfunction of insulin to activate insulin receptor /insulin receptor substrate 1(IRS-1)/phosphoinositide 3-kinase (PI3K)/Akt pathway. Zucker fatty rats (8 weeks) were treated with vehicle (0.5 % methyl cellulose in physiological saline, p.o.), amlodipine (3 mg/kg/day, p.o.), atorvastatin (10 mg/kg/day, p.o.), or the combination of amlodipine plus atorvastatin (3 + 10 mg/kg/day, p.o.) for 28 days, and anti-insulin-like growth factor 1 (IGF-1)/IRS-1/PI3K/Akt pathways were evaluated. Our present immunohistochemical study first demonstrated that a combination of amlodipine plus atorvastatin treatment prevented an arteriosclerotic process compared to the single treatment with amlodipine or atorvastatin with strong recoveries of pTyr IRS-1, pPI3K, and pAkt expressions and with remarkable restraints of IGF-1 and pSer IRS-1. As a result, combination therapy with amlodipine plus atorvastatin showed a strong synergistic effect to prevent atherosclerotic processes. The present study newly suggests a synergistic benefit of combination therapy with amlodipine plus atorvastatin for strong prevention of atherosclerotic processes, which could reduce the clinical risk of cerebrovascular events for obesity patients.

References

  1. J Mol Cell Cardiol. 2000 Dec;32(12):2299-306 - PubMed
  2. Circulation. 1996 May 15;93(10):1809-17 - PubMed
  3. Vascul Pharmacol. 2008 Jan;48(1):47-53 - PubMed
  4. Br J Pharmacol. 2003 Sep;140(2):285-94 - PubMed
  5. Brain Res. 2011 Mar 25;1382:308-14 - PubMed
  6. J Am Coll Cardiol. 2003 Feb 5;41(3):508-15 - PubMed
  7. Curr Neurovasc Res. 2007 Nov;4(4):268-73 - PubMed
  8. Eur J Pharmacol. 2003 Sep 12;477(2):143-52 - PubMed
  9. Bioorg Med Chem Lett. 1999 Oct 18;9(20):2999-3002 - PubMed
  10. Ann N Y Acad Sci. 1965 Oct 8;131(1):447-58 - PubMed
  11. Lancet. 2004 Aug 21-27;364(9435):685-96 - PubMed
  12. Cell Signal. 2010 Apr;22(4):573-7 - PubMed
  13. Can J Cardiol. 2000 Jul;16 Suppl D:8D-11D - PubMed
  14. Neurobiol Dis. 2008 Jan;29(1):132-41 - PubMed
  15. Am J Physiol Heart Circ Physiol. 2010 Jul;299(1):H55-61 - PubMed
  16. Hypertension. 2004 Dec;44(6):956-62 - PubMed
  17. J Cereb Blood Flow Metab. 2012 May;32(5):792-804 - PubMed
  18. Obesity (Silver Spring). 2008 Jan;16(1):82-9 - PubMed
  19. Endocrinology. 1972 May;90(5):1320-30 - PubMed
  20. Atherosclerosis. 2011 Aug;217(2):331-9 - PubMed
  21. Nat Med. 2000 Sep;6(9):1004-10 - PubMed
  22. Brain Res. 2007 Oct 24;1176:143-50 - PubMed
  23. J Endocrinol. 2005 Aug;186(2):367-76 - PubMed
  24. JAMA. 2004 Nov 10;292(18):2217-25 - PubMed
  25. Stroke. 2005 Mar;36(3):670-2 - PubMed
  26. J Clin Invest. 2000 Feb;105(3):311-20 - PubMed
  27. Br J Pharmacol. 1998 Oct;125(4):895-901 - PubMed
  28. FASEB J. 2006 Jan;20(1):169-71 - PubMed
  29. Int Immunopharmacol. 2009 Aug;9(9):1032-41 - PubMed
  30. Diab Vasc Dis Res. 2010 Jan;7(1):20-7 - PubMed
  31. Am J Physiol Heart Circ Physiol. 2010 Sep;299(3):H699-706 - PubMed
  32. Diabetes. 1998 Jan;47(1):13-23 - PubMed
  33. Brain Res. 2011 Jan 12;1368:317-23 - PubMed
  34. Kidney Int. 2005 Dec;68(6):2787-93 - PubMed
  35. Circulation. 1998 Mar 17;97(10):996-1001 - PubMed
  36. Arterioscler Thromb Vasc Biol. 2007 Nov;27(11):2470-5 - PubMed
  37. Lancet. 2003 Apr 5;361(9364):1149-58 - PubMed
  38. J Hum Hypertens. 1995 Mar;9 Suppl 1:S3-9 - PubMed
  39. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2384-93 - PubMed
  40. J Pharm Pharmacol. 2000 Jan;52(1):83-6 - PubMed
  41. Int J Obes Relat Metab Disord. 2003 Dec;27 Suppl 3:S56-60 - PubMed
  42. Thromb Haemost. 2007 May;97(5):714-21 - PubMed
  43. Am J Physiol Regul Integr Comp Physiol. 2006 Jan;290(1):R145-53 - PubMed
  44. J Clin Invest. 1999 Aug;104(4):447-57 - PubMed

Publication Types